Roger Bullock

Summary

Affiliation: Victoria Hospital
Country: UK

Publications

  1. ncbi Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years
    R Bullock
    Kingshill Research Centre, Victoria Hospital, Okus Road, Swindon, UK
    Int J Clin Pract 59:817-22. 2005
  2. ncbi New drugs for Alzheimer's disease and other dementias
    Roger Bullock
    Department of Old Age Psychiatry and Kingshill Research Centre, Avon and Wiltshire Mental Health Trust, Victoria Hospital, Swindon SNI 4HZ, UK
    Br J Psychiatry 180:135-9. 2002
  3. ncbi Not all head-to-head trials are created equal: results from an open-label, short-term study seem inconsistent with previous donepezil literature
    Roger Bullock
    Int J Geriatr Psychiatry 20:85-7; author reply 87-9. 2005
  4. ncbi Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
    Clive Holmes
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK Moorgreen Hospital, Hampshire Partnership Trust, Southampton, UK
    Lancet 372:216-23. 2008
  5. ncbi Future directions in the treatment of Alzheimer's disease
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Expert Opin Investig Drugs 13:303-14. 2004
  6. ncbi Cholinesterase inhibitors and vascular dementia: another string to their bow?
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    CNS Drugs 18:79-92. 2004
  7. ncbi The needs of the caregiver in the long-term treatment of Alzheimer disease
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Alzheimer Dis Assoc Disord 18:S17-23. 2004
  8. ncbi SGS-742 Novartis
    Roger Bullock
    The Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Curr Opin Investig Drugs 6:108-13. 2005
  9. ncbi Galantamine: use in Alzheimer's disease and related disorders
    Roger Bullock
    Kingshill Research Center, Department of Old Age Psychiatry, Avon and Wiltshire Mental Health Trust, Victoria Hospital, Swindon, SNI 4HZ, UK
    Expert Rev Neurother 4:153-63. 2004
  10. ncbi Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Curr Med Res Opin 21:1-10. 2005

Detail Information

Publications37

  1. ncbi Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years
    R Bullock
    Kingshill Research Centre, Victoria Hospital, Okus Road, Swindon, UK
    Int J Clin Pract 59:817-22. 2005
    ..Despite the limitations of current data, the information reviewed in this study may help practising doctors assess the long-term value of ChE-Is in this consistently progressive disease...
  2. ncbi New drugs for Alzheimer's disease and other dementias
    Roger Bullock
    Department of Old Age Psychiatry and Kingshill Research Centre, Avon and Wiltshire Mental Health Trust, Victoria Hospital, Swindon SNI 4HZ, UK
    Br J Psychiatry 180:135-9. 2002
    ..Alzheimer's disease management involves symptomatic drug treatments passed by the National Institute for Clinical Excellence. Disease modification is now the goal...
  3. ncbi Not all head-to-head trials are created equal: results from an open-label, short-term study seem inconsistent with previous donepezil literature
    Roger Bullock
    Int J Geriatr Psychiatry 20:85-7; author reply 87-9. 2005
  4. ncbi Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
    Clive Holmes
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK Moorgreen Hospital, Hampshire Partnership Trust, Southampton, UK
    Lancet 372:216-23. 2008
    ..Our aim was to assess the relation between Abeta(42) immune response, degree of plaque removal, and long-term clinical outcomes...
  5. ncbi Future directions in the treatment of Alzheimer's disease
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Expert Opin Investig Drugs 13:303-14. 2004
    ..This paper reports on the current data that is setting the future directions for research into AD...
  6. ncbi Cholinesterase inhibitors and vascular dementia: another string to their bow?
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    CNS Drugs 18:79-92. 2004
    ..Wherever this is the predominant biological finding, it would be expected that cholinesterase inhibitors would have a similar effect, whatever the condition causing it...
  7. ncbi The needs of the caregiver in the long-term treatment of Alzheimer disease
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Alzheimer Dis Assoc Disord 18:S17-23. 2004
    ..AChEIs play an important role in this effort. Further studies are needed to more closely examine the impact of specific AChEIs on caregiver burden...
  8. ncbi SGS-742 Novartis
    Roger Bullock
    The Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Curr Opin Investig Drugs 6:108-13. 2005
    ..In May 2004, Saegis began enrollment in a phase II trial of SGS-742 in mild-to-moderate AD patients...
  9. ncbi Galantamine: use in Alzheimer's disease and related disorders
    Roger Bullock
    Kingshill Research Center, Department of Old Age Psychiatry, Avon and Wiltshire Mental Health Trust, Victoria Hospital, Swindon, SNI 4HZ, UK
    Expert Rev Neurother 4:153-63. 2004
    ..Overall, galantamine has a broad ranging efficacy and tolerability across an increasing range of conditions...
  10. ncbi Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Curr Med Res Opin 21:1-10. 2005
    ..Evidence suggests that they may be more appropriate for the control of chronic (over weeks to months) mild-to-moderate BPSD...
  11. ncbi Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Curr Med Res Opin 21:1317-27. 2005
    ....
  12. ncbi Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
    Roger Bullock
    Kingshill Research Centre, Swindon, UK
    Curr Med Res Opin 22:483-94. 2006
    ..This retrospective analysis investigated whether younger and older patients showed differential tolerability and efficacy responses to cholinesterase inhibitor treatment...
  13. ncbi Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase
    Roger Bullock
    Kingshill Research Centre, Swindon, UK
    Curr Alzheimer Res 4:277-93. 2007
    ..It may be hypothesized that these dementia types, which are characterized by executive dysfunction, might derive particular benefits from cholinesterase inhibitors such as rivastigmine that inhibit BuChE in addition to AChE...
  14. ncbi Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Dement Geriatr Cogn Disord 17:29-34. 2004
    ..The results of this subgroup analysis indicate that galantamine is effective for long-term maintenance of the cognitive function in patients with AD + CVD and is safe and well tolerated in this patient population...
  15. ncbi Realistic expectations: the management of severe Alzheimer disease
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Alzheimer Dis Assoc Disord 17:S80-5. 2003
    ..In addition, a brief summary of the existing clinical trials conducted in severe AD is presented...
  16. ncbi Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series
    R Bullock
    Department of Old Age Psychiatry, Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Curr Med Res Opin 18:258-64. 2002
    ..A large, placebo-controlled study is warranted to ascertain the full clinical profile of rivastigmine in Parkinson's disease dementia...
  17. ncbi Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Okus Road, Swindon SN1 4HZ, UK
    Int J Geriatr Psychiatry 17:288-9. 2002
  18. ncbi Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Alzheimer Dis Assoc Disord 20:23-9. 2006
    ..Recent studies of the relationship between Alzheimer disease progression, caregiver burden, and healthcare costs emphasize the need for treatments such as memantine that can slow the rate of decline in Alzheimer disease...
  19. ncbi The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis
    R Bullock
    Department of Old Age Psychiatry, Kingshill Research Centre, Victoria Hospital, Swindon, Wilts, UK
    Int J Clin Pract 56:206-14. 2002
    ..If used appropriately, the benefits of rivastigmine seen in clinical practice may prove to be even greater than those reported in clinical trials...
  20. ncbi Atypical antipsychotics: experience and use in the elderly
    R Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, Wilts
    Int J Clin Pract 56:515-25. 2002
    ..This review attempts to summarise the current literature and make some tentative recommendations for each of the commonest atypicals, based on the current evidence...
  21. ncbi Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer disease
    Jan Marcusson
    Department of Geriatric Medicine, Linkoping University Hospital, Linkoping, Sweden
    Alzheimer Dis Assoc Disord 17:S86-91. 2003
    ..Prescribing approved therapies such as galantamine for older patients with AD is recommended...
  22. ncbi Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial
    Timo Erkinjuntti
    Department of Clinical Neurosciences, Helsinki University Central Hospital, Helsinki, Finland
    Lancet 359:1283-90. 2002
    ..We investigated the effects of galantamine in patients with a diagnosis of probable vascular dementia or Alzheimer's disease combined with cerebrovascular disease...
  23. ncbi Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease
    Rafael Blesa
    Hospital Sta Creu i Sant Pau, Barcelona, Spain
    Pharmacogenet Genomics 16:771-4. 2006
    ..These differences may reflect rivastigmine's ability to inhibit BuChE and AChE...
  24. ncbi Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology
    Alistair Burns
    University of Manchester, Manchester, UK
    J Psychopharmacol 20:732-55. 2006
    ..Patients, their carers, and clinicians deserve to be optimistic in a field which often attracts therapeutic nihilism...
  25. ncbi Donepezil for the treatment of agitation in Alzheimer's disease
    Robert J Howard
    Medical Research Council Neurogeneration Research Centre, Institute of Psychiatry, King s College London, London, United Kingdom
    N Engl J Med 357:1382-92. 2007
    ..Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear...
  26. ncbi Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I
    Pauline Aalten
    Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, Maastricht University Hospital, Maastricht, The Netherlands
    Dement Geriatr Cogn Disord 24:457-63. 2007
    ..The aim of this study was to identify neuropsychiatric subsyndromes of the Neuropsychiatric Inventory in a large sample of outpatients with Alzheimer's disease (AD)...
  27. ncbi Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II
    Pauline Aalten
    Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, Maastricht University Hospital, Maastricht, The Netherlands
    Dement Geriatr Cogn Disord 25:1-8. 2008
    ..g. dementia subtypes, dementia severity, medication use, age and gender) in a large sample of outpatients with dementia...
  28. ncbi Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants
    Lori Frank
    The MEDTAP Institute at UBC, Bethesda, MD 20814, USA
    Int Psychogeriatr 18:151-62. 2006
    ....
  29. ncbi Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology
    Jacques Touchon
    CHU, INSERM 361, Montpellier, France
    Curr Med Res Opin 22:49-59. 2006
    ..This retrospective analysis investigated whether AD patients with and without symptoms suggesting concomitant Lewy body pathology demonstrated different responses to therapy...
  30. ncbi Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium
    Philippe H Robert
    Centre Mémoire de Ressources and de Recherche, CHU, Hopital Pasteur, Universite de Nice Sophia Antipolis, 30, avenue de la Voie Romaine, 06002 Nice cedex 1, France
    Eur Psychiatry 20:490-6. 2005
    ..An individually tailored approach taking all these aspects into account is warranted as it may offer more, and better, pharmacological and non-pharmacological treatment opportunities...
  31. ncbi An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia
    Timo Erkinjuntti
    Department of Clinical Neurosciences, Helsinki University Central Hospital, Helsinki, Finland
    Clin Ther 25:1765-82. 2003
    ....
  32. ncbi Prediction of the rate of decline in cognitive function in Alzheimer's disease: a correction
    Sigurd Johnsen
    HPRU Medical Research Centre, University of Surrey, Guildford, UK
    Dement Geriatr Cogn Disord 18:349-50. 2004
  33. ncbi A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease
    Gordon Wilcock
    Department of Care of the Elderly, University of Bristol, Frenchay Hospital, Bristol, UK
    Drugs Aging 20:777-89. 2003
    ..CONCLUSIONS: Significant advantages were found in the treatment response to galantamine (versus donepezil) on cognition as measured by response rates on the MMSE and ADAS-cog/11...
  34. ncbi Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors
    Serge Gauthier
    McGill Centre for Studies in Aging, Verdun, Quebec, Canada
    Curr Med Res Opin 19:707-14. 2003
    ..The panel also aimed to reach consensus on 'whom to switch', 'when to switch' and 'how to switch'. The key findings from that meeting are reported in this review...
  35. ncbi Prediction of the rate of decline in cognitive function in Alzheimer's disease: a model based on simple demographic data and widely used rating scales
    Sigurd Johnsen
    HPRU Medical Research Centre, University of Surrey, Guildford, UK
    Dement Geriatr Cogn Disord 16:276-82. 2003
    ..This model has 96-97% sensitivity and 92-93% specificity. The potential benefits of this model argue for its validation in a prospective study...
  36. ncbi Thoughts on the long-term management of Alzheimer disease
    Roger Bullock
    Alzheimer Dis Assoc Disord 17:S74. 2003
  37. ncbi Can we afford not to have integrated dementia services?
    Roger Bullock
    Age Ageing 36:357-8. 2007